Veracyte (Nasdaq: VCYT) today announced a multi-year partnership with Acerta Pharma, the hematology research and development arm of AstraZeneca (LSE/STO/NYSE: AZN), to provide genomic information that...
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $27.90 to a high of $28.58. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $28.11...
--Provides pathway for long-term revenue growth and margin expansion
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $27.38 to a high of $28.75. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $28.16...
Veracyte, Inc. (Nasdaq: VCYT) today announced new data that advance understanding of the frequency, positive predictive value and co-occurrence of genomic alterations that are targeted by newly available...
Veracyte, Inc. (Nasdaq: VCYT) announced today that new data advancing the understanding of genomic alterations - specifically, NTRK, RET, BRAF and ALK fusions - that are targeted by new precision medicine...
SmarTrend identified a Downtrend for Veracyte Inc (NASDAQ:VCYT) on August 5th, 2019 at $24.26. In approximately 3 months, Veracyte Inc has returned 7.79% as of today's recent price of $22.37.
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $20.09 to a high of $21.44. Yesterday, the shares fell 15.1%, which took the trading range below the 3-day low of $20.79...
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Tuesday reported a loss of $730,000 in its third quarter.
--Genomic Test Volume Grew 24% to 9,941
--Conference call and webcast today at 5:00 p.m. ET to review third quarter 2019 Financial results and the new nasal swab test data
Veracyte, Inc. (Nasdaq: VCYT) today announced data demonstrating the clinical validity of its next-generation Percepta(R) Genomic Sequencing Classifier (GSC) and the clinical utility of its first-generation...
Veracyte, Inc. (Nasdaq: VCYT) announced that data from three studies presented at the annual meeting of the American College of Chest Physicians(R) (CHEST 2019) demonstrate that the Envisia(R) Genomic...
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $24.48 to a high of $25.69. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $24.59...
We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $23.30 to a high of $24.30. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $23.89...
Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the third quarter 2019 and business progress after the close of market on Tuesday, October 22, 2019. Company...
Veracyte, Inc. (Nasdaq: VCYT) today announced that preliminary clinical data for the company's noninvasive nasal swab test - the first of its kind - for early detection of lung cancer will be presented...
Veracyte Inc (NASDAQ:VCYT) traded in a range yesterday that spanned from a low of $23.68 to a high of $24.56. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $24.43...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms. Eastham brings more...
